Search

A two-drug combination may hold the key to overcoming resistance in an aggressive form of non-Hodgkin lymphoma.

… Friday, November 16, 2018 Summary A promising target in the treatment of diffuse large B cell lymphoma (DLBCL) is a protein called BCL2. Drugs that inhibit this protein have been disappointing so far. Researchers have now discovered why DLBCL often proves resistant to this treatment. They have shown

A new era in the treatment of MIBC is on the horizon, with the combination of enfortumab vedotin plus pembrolizumab poised to become the new standard of care in the perioperative treatment of cisplatin-ineligible or cisplatin-refusing patients. MSK’s David Aggen, MD, discusses this, and what new treatment approaches physicians and scientists at MSK are now testing.

… Thursday, November 13, 2025 A Q&A with  David Aggen, MD, PhD , MSK Genitourinary Medical Oncologist and Cellular Therapist A new era in the treatment of muscle-invasive bladder cancer (MIBC) is on the horizon, with the combination of enfortumab vedotin plus pembrolizumab poised to become the new standard

Cell biologist Philipp Niethammer discusses what the zebrafish can teach us about how the body heals.

… Wednesday, July 15, 2015 VIDEO | 00:04 Watch: The Body’s Immune Response In Action Immune cells respond to the site of an injury. Video Details Summary An overactive immune system can lead to diseases, including cancer. In this Q&A, cell biologist Philipp Niethammer talks about his work studying inflammation

At MSK we have developed a highly accurate, low-cost assay, for identifying early-stage oral and anal cancers associated with human papillomavirus (HPV) using liquid biopsy.

… Tuesday, December 10, 2019 Together with my colleagues at Memorial Sloan Kettering Cancer Center, we developed a highly accurate assay for identifying early-stage oral and anal cancers associated with human papillomavirus (HPV) using liquid biopsy. This low-cost technique could be advantageous in early

Learn about the Chief Strategy Officer at MSK, Anaeze Offodile, MD, MPH.

… Tuesday, September 3, 2024 “We are in a moment of historic change in cancer care,” says Anaeze Offodile, MD, MPH . Dr. Offodile joined Memorial Sloan Kettering Cancer Center (MSK) in 2023 as Chief Strategy Officer, after serving as the Executive Director for Clinical Transformation at MD Anderson. Among

MSK researchers are studying why Black patients with breast cancer are more likely to experience heart problems that can result from treatment.

… Thursday, April 15, 2021 The moment she was diagnosed with breast cancer at age 55, Brooklyn resident Debra E. Edwards felt a combination of fear and guilt. “I made a terrible mistake by putting off my mammogram ,” she says now. “When you are busy, you don’t always do the things that are good for your

Learn why people with cancer are prone to falls and how to stay safe this winter.

… Wednesday, December 18, 2019 Summary Falls are a risk for everyone during slushy winter months, but the risk is especially high for people with cancer. MSK physical therapist Jillian Hobson walks readers through what they can do to minimize the chance of taking a tumble. Whether you find yourself walking

Learn how to talk about your lung cancer diagnosis with family, friends and others — including questions about smoking.

… Monday, November 10, 2025 When patients with lung cancer ask social worker Barbara Mitchell for guidance in talking to people about their difficult diagnosis, she lays out her bedrock principles: Your life is NOT an open book just because you have lung cancer. You do NOT need to answer every question

Memorial Sloan Kettering Cancer Center is one of six leading institutions that will share in a $120 million gift from a foundation created by American billionaire Daniel K. Ludwig.

… Tuesday, November 14, 2006 Memorial Sloan Kettering Cancer Center Among the Recipients Memorial Sloan Kettering Cancer Center is one of six leading institutions that will share in a $120 million gift from a foundation created by American billionaire Daniel K. Ludwig. Each of the six US centers will receive

A newly approved imaging technology can identify the location of prostate cancer cells, allowing doctors to choose the best treatment.

… Thursday, May 27, 2021 Prostate cancer diagnosis and treatment took a major step forward today as the US Food and Drug Administration approved an imaging technology that enables doctors to pinpoint the location of prostate cancer cells that would otherwise be hidden in the body. This new technology is